CuroNZ

New Zealand
Wellsford, Auckland, New Zealand
64 21 500 453 ★

Company profile

CuroNZ company profile

Curonz is a clinical stage biotechnology company with a drug portfolio covering the peptide family, Neural Regeneration Peptides (NRPs), which were discovered by Curonz's founding Director, Dr Frank Sieg and where precursor compounds to our clinical molecule NRP2945 were first patented back in 2001. We currently have offices in Delaware, NZ and Australia. We have completed Clinical Phase I in Australia for our lead drug candidate NRP2945 with 49 healthy volunteers. Currently, we are studing NRP2945 in a small Phase II proof of concept study in adults with typical absence epilepsy which is due to finish mid 2019. We are..... For more information, log in to dureach.com to view the full company profile.

Business identity

Contact email
[email protected]
Phone number
64 21 500 453
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Founded
2010-01-01

Headquarters

Headquarters
Wellsford, Auckland, New Zealand
Postal code
0975
Country code
NZ
Continent
Oceania

Capital profile

Funding and company signals

Funding rounds
2
Last funding
Grant / $323K / 2015-12-11
Investors
1
Lead investors
1
Founders
1

Founders and investors

Founders

Frank Sieg

Lead investors

Callaghan Innovation

Investors

Callaghan Innovation

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.